What 12 Analyst Ratings Have To Say About Privia Health Gr
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Privia Health Group (NASDAQ:PRVA) over the past three months, with a recent trend towards lowering price targets. The average 12-month price target is now $26.42, down 16.92%. Despite positive revenue growth and strong net margins, analysts have shown a cautious outlook.
May 15, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Privia Health Group (NASDAQ:PRVA) has received mixed analyst ratings over the past three months, with a recent trend of lowering price targets. The average 12-month price target is now $26.42, down 16.92%. Despite positive revenue growth and strong net margins, analysts have shown a cautious outlook.
The trend of analysts lowering their price targets for PRVA indicates a cautious outlook despite the company's positive revenue growth and strong net margins. This could lead to short-term downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100